Piper Jaffray analyst Danielle Brill believes shares of Acadia Pharmaceuticals offer a favorable risk/reward into the Phase 3 Enhance trial of adjunctive Nuplazid for schizophrenia, which are expected by mid-2019. The analyst's level of conviction for a positive trial outcome remains low, but she believes investor expectations are also low and do not think the opportunity is currently reflected in Acadia's share value. She sees upside potential of 30%-35% on positive data with downside capped at 10% on a negative outcome. Brill keeps an Overweight rating on the shares with a $35 price target.